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Introduction
Liposarcomas are currently classified into 4 different subtypes based on histologic or genetic analysis according to the World Health Organization (WHO), including well-differentiated, dedifferentiated, myxoid, and pleomorphic [1] . The round cell subtype is now representative of a higher grade of the myxoid variant.
The myxoid variant accounts for one-third to one-half of all liposarcomas, commonly occurring in a younger demographic with peak incidence in the fifth decade, in comparison to the dedifferentiated and well-differentiated subtypes which demonstrate peak incidence in the seventh decade. The most common sites of tumor involvement include the lower extremities with a predilection for the medial thigh and popliteal area [2, 3] . The myxoid variant encompasses a continuum of lesions, ranging from predominantly well-differentiated myxoid Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this paper.
areas to predominantly round cell type with poorly differentiated lipoblasts. The higher percentage of round cell areas within the tumor results in increased metastatic potential and mortality [3] [4] [5] .
Magnetic resonance imaging (MRI) features of myxoidround cell liposarcomas are diverse, owing to the continuum of differing myxoid and small cell components. Imaging appearance of typical myxoid-round cell tumors include low signal intensity on T1 given high water content and high signal intensity on T2-weighted sequences of the myxoid element [3] [4] [5] . Additional imaging characteristics include encapsulation, lobulated fat, and diffuse, globular or nodular intense enhancement. T1-hyperintense fatty septa can help differentiate these tumors from cystic lesions [5, 6] .
With regard to treatment, sarcomas are generally considered radiation resistant [7] . Local control and preservation of functional outcome is the goal for preoperative radiation therapy [7] . Currently, use of radiotherapy (RT) is accepted in both the pre-and postoperative settings for local control after a National Cancer Institute of Canada clinical trial demonstrated comparable results [7] . Myxoid liposarcoma is unusual in that it is shown to be highly sensitive to radiation therapy and can be treated successfully with both adjuvant and neoadjuvant radiation therapy. The mechanism of tumor response to RT is unknown; however, it is thought to be related to the distinctive vasculature of the tumor [7] .
We present a case of a myxoid round cell tumor with excellent neoadjuvant radiation therapy response on MRI with histopathologic correlation.
Case report
An 81-year-old male presented with an enlarging left thigh mass and pain. Initial MRI demonstrated a 7 × 7 × 12-cm encapsulated intermuscular mass within the left thigh deep to the sartorius muscle and superficial femoral neurovascular bundle (Fig. 1) . Typical imaging characteristics of myxoid liposarcoma were seen, including T1-hyperintense fatty lobular regions comprising approximately 50% of the mass, marked T2 hyperintensity of nonfatty components, and postcontrast avid nodular enhancement predominantly of the nonfatty components. Ultrasound-guided biopsy yielded a tissue diagnosis of liposarcoma, myxoid type with round cell components, grade 2 (stage IIb). Patient subsequently underwent neoadjuvant radiation therapy with 50 Gy in 2 Gy/fraction using an intensitymodulated radiotherapy plan. Postradiation therapy MRI showed a decreased size of the mass, measuring 5 × 5 × 7 cm, with predominantly T1-hyperintense fatty regions and only minimal residual enhancement (Fig. 2 ). There were minimal T2-hyperintense areas corresponding to likely residual myxoid elements. Tumor resection was subsequently performed, with pathologic examination yielding a 6-cm mesenchymal mass (Fig. 3) with rare foci of residual myxoid liposarcoma (<10% viable tumor exhibiting maturation of tumor cells) in a background of extensive treatment effect. Round cell morphology characterizing the original biopsy was not identified. Post-treatment tumor was classified as grade I (Fig. 4) .
Discussion
Myxoid liposarcoma and round cell liposarcoma have a common chromosomal translocation t(12;16)(q13;p11) resulting in the fusion transcript of the TLS and CHOP genes and are now recognized as a continuum of the same entity [5, 6, 8] . MRI features of myxoid-round cell liposarcoma have prognostic significance [6] . According to Tateishi et al., imaging characteristics associated with improved overall survival and lower grade tumors include thin septa or tumor capsule. Pronounced enhancement was the most significant prognostic factor with regard to adverse outcomes [6] .
Previous studies have illustrated that areas with greater than 5% nonfatty, nonmyxoid, enhancing components are associated with higher grade tumors [4] . According to Tateishi et al., patterns of enhancement including pronounced enhancement mainly at the periphery of lesions and globular or nodular enhancement within the lesion center were characteristic of intermediate to high-grade tumors [6] . Previously reported pathologic examinations have demonstrated round cell components to be located at the periphery of lobules, adjacent to fibrous septa extending through the tumor and surrounding large vessels [6] . Given these concordant findings, MRI enhancement pattern can potentially be used to stratify tumor grade based on round cell component.
Myxoid liposarcoma is unique with regard to its unusual pattern of metastatic spread to extra pulmonary sites including bone, retroperitoneum, paraspinal regions, and opposite extremity, with skeletal metastases reported as the most common [4, 5, 8] . According to Jagannathan et al., osseous metastases that are detected with ease on MRI are difficult to identify on conventional computed tomography and positron emission tomography-computed tomography secondary to lack of significant osseous destruction and decreased fluorodeoxyglucose (F18-FDG) avidity owing to the myxoid matrix. Therefore, several investigators recommend wholebody MRI for screening, especially in the setting of higher grade tumors [4] . 
